Eli Lilly vs Takeda Pharmaceutical
LLY and TAK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LLY and TAK compare
Eli Lilly grew revenue faster over the last twelve months (45.5% versus −1.7% for Takeda Pharmaceutical).
Eli Lilly keeps more of each dollar of sales as profit, with a net margin of 31.9% compared with −3.4% at Takeda Pharmaceutical.
Eli Lilly pays a dividend yielding 0.47%; Takeda Pharmaceutical does not pay one.
Eli Lilly scores higher on the StockData Score (20 against 5 for Takeda Pharmaceutical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LLY | TAK |
|---|---|---|
| Size and price | ||
| Market cap | $1.3T | – |
| Share price | $1417.54 | $20.91 |
| Change, 1 year | 74.2% | 51.9% |
| Change, 5 years | 435% | 46.7% |
| Beta (5Y) | 0.52 | 0.22 |
| Employees | 50K | 47K |
| StockData Score | ||
| Total score | 20 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 6 (better) | 0 |
| Performance score | 5 (better) | 2 |
| Health score | 4 (better) | 3 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 46.0× | – |
| P/S | 15.4× | – |
| P/B | 33.1× | – |
| EV/EBITDA | 37.3× | – |
| PEG | 0.93 | – |
| Fair value | $1125.50 | – |
| Margin of safety | −25.9% | – |
| Growth | ||
| Revenue growth (TTM) | 45.5% (better) | −1.7% |
| Revenue growth, 5Y average | 21.6% (better) | 7.1% |
| Net income growth (TTM) | 49.8% (better) | −241% |
| EPS growth (TTM) | 50.7% (better) | −244% |
| EPS growth, 5Y average | 27.6% | – |
| Profitability | ||
| Gross margin | 83.6% (better) | 65.1% |
| Operating margin | – | 0.14% |
| Net margin | 31.9% (better) | −3.4% |
| FCF margin | – | 19.2% |
| Return on equity | 86.1% (better) | −2.1% |
| Return on invested capital | – | 0.04% |
| Financial health | ||
| Debt / equity | 1.23 | 0.66 (better) |
| Net debt / EBITDA | 1.21 (better) | 5.89 |
| Interest coverage | – | 0.0× |
| Current ratio | 1.39 (better) | 1.09 |
| Altman Z-score | 8.52 | – |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 0.47% | – |
| Payout ratio | 21.7% | – |
| Years of dividend growth | 9 | – |
| Dividend growth, 5Y average | 15.2% | – |
| Buyback yield | 0.44% | – |
| Shareholder yield | 0.91% | – |
| Ownership | ||
| Held by institutions | 83.7% | 6.0% |
| Held by insiders | 10.4% | 0.22% |
| Insider net buying, 12 months | −$2.3B | −$13.1M (better) |
| Superinvestors holding | 3 | – |
| Short interest, % of float | 0.83% | – |
Go deeper
- LLY stock overview
- LLY income statement
- LLY valuation and score
- TAK stock overview
- TAK income statement
- TAK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.